Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2018

Open Access 01-12-2018 | Research article

Evaluation of a population-level strategy to promote tobacco treatment use among insured smokers: a pragmatic, randomized trial

Authors: Jennifer B. McClure, Melissa L. Anderson

Published in: BMC Public Health | Issue 1/2018

Login to get access

Abstract

Background

Most smokers do not use evidence-based smoking cessation treatment. Increasing utilization of these services is an important public health goal. Health care systems and insurers are well positioned to support this goal within their patient populations. We tested whether a brief, mail-based intervention increased utilization of tobacco cessation services among insured smokers.

Methods

Adult smokers were identified via automated health plan data and randomized to one of five treatment arms (n = 4767). Randomization was stratified by gender, age, and type of health plan coverage. Three arms received a letter containing motivational content and treatment referral information. Motivational content emphasized either the financial, health, or values-based benefits of quitting. One arm received a referral letter with no motivational content, and one arm received no letter. Enrollment in the referred tobacco cessation program was monitored for 5 months. Treatment was available to all participants through their insurance.

Results

Across all four letter conditions, 0.8% of participants enrolled in tobacco treatment compared to 0.9% in the no letter reference group (p = .69). No single letter condition was superior to the others (p = .71), but treatment uptake was greater among participants who received their care and coverage from the health plan versus those with insurance coverage only (1.2% vs. 0.3%, p < .01).

Conclusions

A one-time, mailed letter is not a cost-effective strategy for promoting use of covered smoking cessation treatment within large health plan populations, particularly when the message source is an insurance provider only and does not also provide clinical care. Health plans and insurers should consider alternative outreach efforts to promote treatment uptake among smokers.

Trial registrations

TRN registered retrospectively with ISRCTN registry (www.​isrctn.​com). Registered on 11/01/2018. Registration number: ISRCTN32311137.
Literature
1.
Jamal A, Homa DM, O’Connor E, Babb SD, Caraballo RS, Singh T, Hu SS, King BA. Current cigarette smoking among adults - United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 2015;64(44):1233–40.CrossRefPubMed
2.
Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged >or=18 years --- United States, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60(35):1207–12.
3.
U.S. Department of Health and Human Services. The health consequences of smoking: 50 years of progress. A report of the surgeon general. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health; 2014.
4.
Javitz HS, Zbikowski SM, Deprey M, TA MA, JB MC, Richards J, Catz SL, Jack LM, Swan GE. Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation. Transl Behav Med. 2011;1(1):182–90.CrossRefPubMed
5.
Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF, Froelicher ES, Goldstein MG, Healton C, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville: U.S. Department of Health and Human Services. Public Health Service; 2008.
6.
Centers for Disease Control and Prevention. Quitting smoking among adults--United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2011;60(44):1513–9.
7.
Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med. 2008;34(2):102–11.CrossRefPubMed
8.
Curry SJ, Grothaus LC, McAfee T, Pabiniak C. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med. 1998;339(10):673–9.CrossRefPubMed
9.
Fiore MC, Novotny TE, Pierce JP, Giovini GA, Hatziandreu EJ, Newcomb PA, Sureawicz TS, Davis RM. Methods used to quit smoking in the United States. Do cessation programs help? JAMA. 1990;263(20):2760–5.CrossRefPubMed
10.
Vidrine JI, Shete S, Li Y, Cao Y, Alford MH, Galindo-Talton M, Rabius V, Sharp B, Harmonson P, Zbikowski SM, et al. The ask-advise-connect approach for smokers in a safety net healthcare system: a group-randomized trial. Am J Prev Med. 2013;45(6):737–41.CrossRefPubMedPubMedCentral
11.
Gilbert H, Sutton S, Morris R, Petersen I, Galton S, Wu Q, Parrott S, Nazareth I. Effectiveness of personalised risk information and taster sessions to increase the uptake of smoking cessation services (Start2quit): a randomised controlled trial. Lancet. 2017;389(10071):823–33.CrossRefPubMedPubMedCentral
12.
Gilbert H, Sutton S, Morris R, Petersen I, Wu Q, Parrott S, Galton S, Kale D, Magee MS, Gardner L, et al. Start2quit: a randomised clinical controlled trial to evaluate the effectiveness and cost-effectiveness of using personal tailored risk information and taster sessions to increase the uptake of the NHS stop smoking services. Health Technol Assess. 2017;21(3):1–206.CrossRefPubMedPubMedCentral
13.
Alesci NL, Boyle RG, Davidson G, Solberg LI, Magnan S. Does a health plan effort to increase smokers’ awareness of cessation medication coverage increase utilization and cessation? Am J Health Promot. 2004;18(5):366–9.CrossRefPubMed
14.
Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.CrossRefPubMed
15.
16.
Kahneman D, Tversky A. Prospect theory: an analysis of decision under risk. Econometrica. 1979;47(2):263–92.CrossRef
17.
West R. Time for a change: putting the Transtheoretical (stages of change) model to rest. Addiction. 2005;100(8):1036–9.CrossRefPubMed
Metadata
Title
Evaluation of a population-level strategy to promote tobacco treatment use among insured smokers: a pragmatic, randomized trial
Authors
Jennifer B. McClure
Melissa L. Anderson
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2018
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-018-5119-0

Other articles of this Issue 1/2018

BMC Public Health 1/2018 Go to the issue

Research article

Self-perceived ability to cope with stress and depressive mood without smoking predicts successful smoking cessation 12 months later in a quitline setting: a secondary analysis of a randomized trial

Research article

Income inequality in uptake of voluntary versus organised breast cancer screening: evidence from the British Household Panel Survey

Research article

Statewide dissemination and implementation of physical activity standards in afterschool programs: two-year results

Research article

Development and validation of a new knowledge, attitude, belief and practice questionnaire on leptospirosis in Malaysia

Research article

Socio-demographic and sexual practices associated with HIV infection in Kenyan injection and non-injection drug users

Research article

Using a cascade approach to assess condom uptake in female sex workers in India: a review of the Avahan data